STTR Phase I: Aptamer Biosensors with the Longevity and Technology Compatibility Required for Continuous Biosensing Devices Beyond Glucose

STTR 第一阶段：适体生物传感器具有葡萄糖以外的连续生物传感设备所需的寿命和技术兼容性

• 批准号: 2212221
• 负责人: Aleksandar Karajic
• 金额: $ 25.59万
• 依托单位: KILELE HEALTH LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-15 至 2023-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2212221&HistoricalAwards=false
• 关键词: STTR; Phase; Aptamer; Biosensors; Longevity

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to improve clinical outcomes for patients with wearable biosensor needs. This project will develop wearable continuous glucose biosensor platforms to address a broad set of disease and wellness applications, such as measuring additional molecules relevant to diabetes management, improving management of cardiovascular diseases, and therapeutic drug monitoring to customize dosages. In addition to impacting human health (particularly for chronic diseases) in the United States, the commercial market is significant and valued at approximately $120 B/year. Furthermore, these biosensors will provide data directly to patients to inform their decisions. This Small Business Technology Transfer (STTR) Phase I project will address the limitations which have prevented continuous diagnostic monitoring platforms from adding clinical utility beyond sensing glucose with enzymatic sensors. Unlike enzymatic glucose sensors, electrochemical aptamer sensors are rapidly adaptable to measuring other molecules in the body with high specificity and sensitivity. However, aptamer sensors currently degrade rapidly in live animals (6-12 hours) and must be inserted through a highly-invasive incision. This STTR Phase I project will demonstrate robust and longer-lasting functioning of aptamer biosensors in a real biofluid environment. It will use a software-enabled method in which only one electrode is inserted, making the resulting device truly minimally invasive.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小型企业技术转移（STTR）I期项目的更广泛的影响/商业潜力是改善具有可穿戴生物传感器需求的患者的临床结果。 该项目将开发可穿戴的连续葡萄糖生物传感器平台，以解决广泛的疾病和健康应用，例如测量与糖尿病管理相关的其他分子，改善心血管疾病的管理以及治疗性药物监测以自定义剂量。 除了影响美国的人类健康（尤其是慢性疾病）外，商业市场还很重要，价值约为每年120美元。 此外，这些生物传感器将直接向患者提供数据以告知他们的决定。这个小型企业技术转移（STTR）I期项目将解决已阻止连续诊断监测平台添加临床实用程序的局限性，而不是通过酶传感器传感葡萄糖。与酶促葡萄糖传感器不同，电化学适体传感器迅速适应以高特异性和敏感性测量体内其他分子。但是，当前的适体传感器在活动物（6-12小时）中迅速降解，必须通过高度侵入性的切口插入。 该STTR I期项目将证明适体生物传感器在实际生物流体环境中的稳健和持久功能。它将使用一个支持软件的方法，其中仅插入一个电极，从而使所得的设备真正至少具有侵入性。该奖项反映了NSF的法定任务，并且使用基金会的智力优点和更广泛的影响评估标准，被认为值得通过评估来获得支持。